Today: 7 February 2026
Subscribe
Browse Category

LSE:GSK News 28 January 2026 - 6 February 2026

GSK share price dips at London open after 52-week high — what investors watch next

GSK share price dips at London open after 52-week high — what investors watch next

GSK shares fell 0.8% to 2,162 pence in early London trading Friday, retreating from multi-decade highs after a post-earnings rally. The company forecast 2026 turnover growth of 3% to 5%, with currency effects expected to cut reported growth by about 3%. GSK announced a 70 pence dividend target for 2026 and completed £1.4 billion of a £2 billion buyback. President David Redfern sold 100,000 shares at £21.09 each.
6 February 2026
····
FTSE 100 slips from highs as Bank of England looms; Shell results hit UK shares today

FTSE 100 slips from highs as Bank of England looms; Shell results hit UK shares today

UK stocks slipped Thursday, with the FTSE 100 down 0.2% to 10,382 by 1052 GMT as investors awaited the Bank of England’s rate decision. Shell fell 1.9% after missing profit forecasts but kept its buyback pace. Vodafone dropped 4.7% after launching a €500 million buyback. The STOXX 600 lost 0.5% amid mixed European earnings.
5 February 2026
········
GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK shares surged 6.9% Wednesday to a 25-year high after reporting 2025 sales of £32.7 billion and raising its 2026 outlook. The company projects 2026 revenue growth of 3%–5% and expects core profit and earnings per share to rise 7%–9%. Investors remain cautious about slower growth and looming patent expirations. London markets await Thursday’s open for further reaction.
5 February 2026
····
FTSE 100 breaks 10,400 as Zurich-Beazley bid and GSK lift UK stocks ahead of BoE

FTSE 100 breaks 10,400 as Zurich-Beazley bid and GSK lift UK stocks ahead of BoE

FTSE 100 rose 1.0% to 10,418.51 by mid-morning Wednesday, with Beazley shares jumping nearly 9% after Zurich raised its takeover bid. GSK gained 2.3% on a positive long-term outlook. AI-linked stocks like RELX and LSEG fell again after recent tech sector jitters. Sterling hit a five-month high against the euro ahead of the Bank of England’s rate decision.
4 February 2026
·······
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares rose 1.4% Wednesday morning after new CEO Luke Miels issued a 2026 outlook projecting slower sales growth and warning of possible weakness in vaccines and general medicines. The company reported 2025 sales up 7% to £32.67 billion and forecast 2026 turnover growth of 3% to 5%. Investors remain focused on GSK’s ability to manage looming HIV patent expirations.
4 February 2026
····
GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK forecast slower revenue growth of 3% to 5% for 2026 under new CEO Luke Miels, citing weaker vaccine and general medicines sales. Shares rose 1.4% after an initial drop. Q4 core earnings per share reached 25.5 pence, with sales up 8% to £8.62 billion. The company is reviewing cost-saving measures and manufacturing changes but has not announced immediate cuts.
4 February 2026
····
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
······
GSK share price rises into earnings week — what traders watch before Feb 4 results

GSK share price rises into earnings week — what traders watch before Feb 4 results

GSK shares closed Friday up 1.3% at 1,876.5 pence, with 8.9 million shares traded. The company will report fourth-quarter and full-year results on Feb. 4, with consensus forecasts at £8.5 billion core turnover and 23p core EPS. Investors are watching Shingrix, Arexvy, and HIV drug sales. The FTSE 100 rose for a seventh straight month as the pound weakened.
1 February 2026
·····
GSK stock price ends week higher as Feb 4 earnings loom — what investors watch next

GSK stock price ends week higher as Feb 4 earnings loom — what investors watch next

GSK shares rose 1.3% to 1,876.5 pence in London on Friday, extending a two-day rally ahead of fourth-quarter results due Feb. 4. Investors are watching for 2026 guidance and updates on vaccine and specialty drug demand. The stock remains about 9% below its December high. GSK recently agreed to buy RAPT Therapeutics for $2.2 billion and signaled changes in its HIV joint venture.
31 January 2026
····
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares rose 0.34% to 1,823.75 pence early Thursday in London after a 2.42% drop Wednesday. Citi began coverage with a Neutral rating and a 1,900p target, noting pipeline improvements but warning on valuation. Investors await GSK’s Feb. 4 earnings for updates on vaccines, HIV treatments, and 2026 guidance. GSK’s RSV vaccine Arexvy recently gained EU approval for adults 18 and older.
29 January 2026
····
FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 fell 0.3% to 10,177.85 as a stronger pound hit overseas earners. Gold reached a record above $5,300 an ounce, boosting miners, while Marston’s dropped up to 16% on flat 17-week sales. Traders awaited the U.S. Fed’s policy decision later Wednesday. Oil prices eased but held near four-month highs after U.S. supply disruptions.
28 January 2026
·········
1 2 3 … 5

Stock Market Today

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

Macquarie Group share price slips 2% after APRA eases liquidity curbs — what to watch next week

7 February 2026
Macquarie Group shares fell 2.17% to A$207.83 Friday, marking a third straight decline as the ASX 200 slid 2%. Australia’s regulator trimmed liquidity requirements for Macquarie Bank after improvements in controls. Macquarie Asset Management announced two UK utility deals, including full ownership of Last Mile Infrastructure and the purchase of Energy Assets Group. Investors await Tuesday’s operational briefing.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 1:05 AM EST Crude Oil Prices Rise on Dollar Weakness, Geopolitical Tensions February 7, 2026, 12:52 AM EST. Crude oil prices edged higher on Friday, supported by a weaker U.S. dollar and escalating geopolitical risks in the Middle East. March WTI crude gained 0.41%, rebounding from early losses, while gasoline prices rose 1.38%. Doubts over a U.S.-Iran nuclear deal loom after reports of Iran's refusal to halt uranium enrichment, raising the risk of military action and potential disruption of vital shipping routes. Additionally, a surge in U.S. consumer
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Go toTop